We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-2.98%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.33B
AUM Growth
-$428M
Cap. Flow
-$106M
Cap. Flow %
-2.44%
Top 10 Hldgs %
30.21%
Holding
157
New
4
Increased
80
Reduced
15
Closed
21

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$22.8M
2
XLO icon
Xilio Therapeutics
XLO
+$20.3M
3
AURA icon
Aura Biosciences
AURA
+$18M
4
CMPX icon
Compass Therapeutics
CMPX
+$17.7M
5
AGL icon
Agilon Health
AGL
+$10.2M

Top Sells

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$49M
2
ALLK
Allakos
ALLK
+$32.4M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$26.3M
4
BOLT icon
Bolt Biotherapeutics
BOLT
+$20.9M
5
OSH
Oak Street Health, Inc.
OSH
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.41%
2 Consumer Staples 1.28%
3 Industrials 0.73%
4 Financials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNMD icon
51
CONMED
CNMD
$1.48B
$28.7M 0.66%
202,500
+40,000
+25% +$5.67M
LENZ
52
LENZ Therapeutics
LENZ
$168M
$25.8M 0.6%
296,987
+314
+0.1% +$26K
SRRA
53
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$25.8M 0.6%
1,184,793
-129,204
-10% -$2.85M
XENT
54
DELISTED
Intersect ENT, Inc
XENT
$25.7M 0.59%
940,000
-280,000
-23% -$7.59M
MIRM icon
55
Mirum Pharmaceuticals
MIRM
$6.02B
$24.5M 0.57%
1,538,814
+13,191
+0.9% +$205K
RXDX
56
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$24.5M 0.56%
618,407
+8,271
+1% +$259K
XENE icon
57
Xenon Pharmaceuticals
XENE
$6.21B
$24.1M 0.56%
771,367
+188,267
+32% +$5.63M
BMRN icon
58
BioMarin Pharmaceuticals
BMRN
$13.3B
$23.3M 0.54%
264,000
+10,500
+4% +$866K
MDGL icon
59
Madrigal Pharmaceuticals
MDGL
$11.9B
$22.8M 0.53%
269,400
+6,900
+3% +$567K
LUNG icon
60
Pulmonx
LUNG
$97.9M
$22.4M 0.52%
700,000
– –
DVAX
61
DELISTED
Dynavax Technologies
DVAX
$22.2M 0.51%
1,576,894
+146,973
+10% +$2.42M
WST icon
62
West Pharmaceutical
WST
$24.8B
$21.3M 0.49%
45,500
+15,500
+52% +$6.67M
MRSN
63
DELISTED
Mersana Therapeutics
MRSN
$20.2M 0.47%
129,958
+9,130
+8% +$1.78M
GH icon
64
Guardant Health
GH
$22.4B
$20M 0.46%
200,000
– –
XLO icon
65
Xilio Therapeutics
XLO
$60.5M
$19.1M 0.44%
+85,078
New +$20.3M
LFST icon
66
Lifestance Health
LFST
$4.55B
$19M 0.44%
2,000,000
+312,500
+19% +$3.31M
LEGN icon
67
Legend Biotech
LEGN
$4B
$18.8M 0.43%
403,584
+88,366
+28% +$4.48M
ANAB icon
68
AnaptysBio
ANAB
$1.64B
$18.7M 0.43%
538,700
+2,868
+0.5% +$91K
RLAY icon
69
Relay Therapeutics
RLAY
$4.37B
$18.4M 0.42%
597,767
+128,207
+27% +$4.05M
IMRX icon
70
Immuneering
IMRX
$293M
$17.6M 0.41%
1,089,816
– –
AURA icon
71
Aura Biosciences
AURA
$796M
$17.1M 0.4%
+1,008,114
New +$18M
CMPX icon
72
Compass Therapeutics
CMPX
$400M
$16.9M 0.39%
+5,328,088
New +$17.7M
ICVX
73
DELISTED
Icosavax, Inc. Common Stock
ICVX
$16.8M 0.39%
735,504
+1,289
+0.2% +$33.3K
SPRO icon
74
Spero Therapeutics
SPRO
$71.2M
$15.1M 0.35%
945,313
+3,770
+0.4% +$59.9K
AMRN
75
Amarin Corp
AMRN
$298M
$14.9M 0.34%
220,985
+4,985
+2% +$413K
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Rock Springs Capital Management held 157 positions worth $4.33B, down 9% from $4.76B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2021 filing shows 4 new, 80 increased, 15 reduced and 21 closed positions. Its largest new stake was Xilio Therapeutics: 85,078 shares worth $19.1M. The largest sale was Teleflex, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q4 2021 buy was Xilio Therapeutics: 85,078 shares worth $19.1M.
  • Rock Springs Capital Management added most to Baxter International in Q4 2021, an estimated $22.8M increase.
  • Rock Springs Capital Management's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $15.4M.
  • Rock Springs Capital Management fully exited Teleflex in Q4 2021, selling an estimated $49M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $4.33B portfolio in Q4 2021.
  • Rock Springs Capital Management opened 4 new positions and closed 21 in Q4 2021.
  • Rock Springs Capital Management's portfolio value fell 9% quarter-over-quarter to $4.33B.

Based on Rock Springs Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.